Olusegun Onabajo

Olusegun (Segun) Onabajo is an Associate Director in Translational Biomarkers at Takeda, where he leads biomarker strategy for inflammatory bowel disease (IBD) therapeutics. He previously served as a Senior Principal Scientist at Genentech, focusing on translational biomarker development across immunology programs.

Before transitioning to industry, Segun was a Staff Scientist at the Laboratory of Translational Genomics at the National Cancer Institute, where he evaluated next-generation sequencing approaches to functionally characterize GWAS loci associated with infectious diseases.

Segun earned his PhD in Molecular Genetics with a concentration in Immunology from the University of Maryland, followed by postdoctoral training in infectious disease and genomics. His translational research in IBD leverages computational and machine learning methods to deconvolute biomarker data from heterogeneous gut populations and identify gene signatures reflective of drug response. He is particularly interested in uncovering mechanisms of treatment resistance and designing combination-therapy strategies to enhance therapeutic efficacy.